Can my employer choose to cover GLP-1 medications?

Yes, and many employers actively control this decision. Approximately 60% of Americans with employer-sponsored insurance are in self-funded plans — where the employer, not an insurance carrier, pays claims directly. Self-funded employers set their own drug formularies and can add or remove covered medications at any time, typically at the start of a new plan year. Even fully-insured employers can negotiate formulary changes with their insurance carrier, particularly at renewal time.

Do GLP-1 medications actually save employers money?

Multiple large employers and actuarial analyses have concluded that GLP-1 coverage for obesity management generates a positive return on investment over a 3–5 year time horizon. The case rests on preventing downstream claims: a single prevented diabetes diagnosis saves $9,600+ per year in avoided management costs; a single avoided cardiac hospitalization saves $50,000–$150,000; and GLP-1 medications have demonstrated a 73% reduction in new diabetes onset and a 20% reduction in cardiovascular events in large clinical trials. Employers like large financial institutions and healthcare companies have added coverage based on this actuarial analysis.

How do I approach HR about adding GLP-1 coverage?

The most effective approach frames the request as a business case, not a personal need. HR and benefits decision-makers respond to data about downstream cost savings, productivity impact, and competitive positioning. A formal written request with cost-benefit data is more effective than a verbal conversation. Group requests from multiple employees are significantly more effective than individual requests. The best timing is during the benefits review season (typically Q3–Q4 for calendar-year plans) when formulary changes are being discussed.

What if my employer already offers GLP-1 coverage but my plan still denies it?

If GLP-1 medications are on your employer's formulary but your claim is still denied, the issue is likely prior authorization criteria rather than a formulary exclusion. Review your Summary Plan Description (SPD) for the PA requirements, and work with your prescribing physician to ensure the documentation meets those specific criteria. A prior authorization support letter from your physician — documenting your BMI, comorbidities, and prior treatment history — resolves most denials that reach the appeal stage.

Employer Advocacy Toolkit · Updated May 2026

How to Get Your Employer to Cover GLP-1 Medications

May 2026 | BetterNewLives.com

If you have employer-sponsored insurance, there's a good chance your employer — not your insurer — is making the coverage decision. About 60% of Americans with employer health benefits are in self-funded plans, where the company pays medical claims directly and sets its own drug formulary. That means your employer can add GLP-1 coverage at any time, and employees who ask effectively can make it happen.

This toolkit gives you everything you need: the business case data employers actually respond to, a step-by-step engagement strategy, templates for individual and group requests, and guidance on what to do if the first answer is no.

Is your employer self-funded? Signs your plan is self-funded: your insurance card says "Administered by [UHC/Aetna/BCBS]" but the company name is also on the card. Your plan documents (Summary Plan Description) say "self-funded" or "self-insured." Or you work for a company with 200+ employees — most large employers are self-funded. If you're unsure, ask your HR benefits administrator.

60%

of employer-insured Americans are in self-funded plans where the employer sets formulary

~40%

of large employers now cover GLP-1 anti-obesity medications (up from ~25% in 2023)

$9,600/yr

Avg annual cost of one employee developing type 2 diabetes — what employers are trying to avoid

73%

Reduction in new diabetes onset with semaglutide (SELECT trial, NEJM 2024)

The Employer's Perspective: Why This Is a Business Decision

HR and benefits directors don't think about GLP-1 coverage the way patients do. They think about it as a line item in a claims budget — and they're asking one question: does the cost of covering these drugs come out ahead of the cost of not covering them?

Increasingly, the actuarial answer is yes. Here's the financial logic employers are working with:

Preventable downstream claims: An employee who develops type 2 diabetes generates approximately $9,600–$13,700 in incremental annual claims — for decades. A cardiovascular hospitalization costs the plan $50,000–$150,000 in a single event. GLP-1 therapy that prevents these outcomes pays for itself rapidly.
Absenteeism and productivity: Employees with obesity miss an estimated 1.8 additional workdays per year, and disability claims are substantially higher. Both have measurable financial impact for self-insured employers.
Competitive talent considerations: Large financial institutions, technology companies, and healthcare systems have added GLP-1 coverage and publicized it. For employers competing for talent, this has become a differentiator.
Manageable cost with guardrails: Employers who add GLP-1 coverage typically do so with prior authorization requirements — BMI thresholds, comorbidity documentation, step therapy — that appropriately limit utilization to high-need patients. This limits actuarial exposure while providing coverage to those with genuine clinical need.

How to Approach This Strategically

Confirm whether your plan is self-funded and identify the decision-maker. Check your Summary Plan Description (SPD) for "self-funded" or "self-insured" language. Identify who manages benefits decisions — usually a VP of Benefits, Chief People Officer, or Benefits Manager. In larger companies, there may be a Benefits Advisory Committee.
Determine the benefits review calendar. Formulary changes for a calendar-year plan are typically decided in Q3 (July–September) for the following January. This is the highest-leverage window to make your request. Requests submitted outside review season may not be considered until the next cycle.
Build a coalition before submitting. A single employee request is easy to deprioritize. Requests from 5, 10, or 20 employees — especially across departments and seniority levels — are much harder to ignore. Identify colleagues who would benefit and coordinate a joint submission. You don't need to disclose personal health information to do this — the request can be framed around the general principle of obesity medication access.
Submit a formal written request — not a verbal conversation. Written requests create a paper trail, are taken more seriously, and give the decision-maker something to bring to a committee. Use the template below as your starting point.
Follow up in 2–3 weeks and offer to provide additional data. Offer to connect HR with resources from the Obesity Medicine Association, the Business Group on Health, or actuarial analyses from major benefits consultants. Showing you've done the research signals this is a serious, considered request.
If the first answer is no, ask for the decision to be revisited at the next benefits review. "No" often means "not this cycle." Ask to be notified when the next formulary review begins and request that GLP-1 coverage be included on the agenda.

Group Request Letter Template

This template is designed to be signed by multiple employees. More signatories = more impact. Adjust the number of signatories and department references to match your situation.

📋 Group Employee Request Letter — Employer GLP-1 Coverage

[DATE]

[BENEFITS DECISION-MAKER NAME OR "Benefits Administration Team"]
[COMPANY NAME]

RE: Request to Add GLP-1 Anti-Obesity Medication Coverage — [PLAN YEAR] Benefits Review

Dear [NAME / Benefits Team],

We are writing as a group of [COMPANY NAME] employees to formally request that the company consider adding coverage for GLP-1 receptor agonist medications — including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) — to our health benefits plan for [PLAN YEAR].

We recognize that benefits decisions involve careful cost-benefit analysis, and we want to present the actuarial and clinical data that has led a growing number of leading employers to make this change.

THE EMPLOYER FINANCIAL CASE:

Preventing Expensive Downstream Events
• Employees with obesity incur $1,800–$6,700 more in annual healthcare claims than healthy-weight peers
• The annual incremental cost of managing type 2 diabetes after diagnosis: $9,600–$13,700 per employee
• GLP-1 medications reduce new diabetes onset by 73% in high-risk individuals (NEJM, 2024)
• GLP-1 medications reduce major cardiovascular events by 20% (SELECT trial, NEJM 2023)
• A single prevented cardiac hospitalization saves $50,000–$150,000 in claims

Productivity and Absenteeism
• Employees with obesity lose an estimated 1.8 additional workdays per year to absenteeism
• GLP-1 therapy has demonstrated improvements in physical function, energy, and quality of life
• Disability and short-term leave claims are substantially higher among employees with obesity-related conditions

Competitive and Retention Considerations
• Approximately 40% of large employers now cover anti-obesity GLP-1 medications
• Major employers across financial services, technology, healthcare, and manufacturing have added coverage
• For employees managing chronic metabolic conditions, benefits coverage is an increasingly important factor in employment decisions

COST MANAGEMENT THROUGH GUARDRAILS:
Employers who have added this coverage typically do so with prior authorization requirements — BMI thresholds (≥30, or ≥27 with comorbidity), documented comorbidities, and step therapy — that limit utilization to those with genuine clinical need and manage actuarial exposure responsibly.

We would welcome the opportunity to discuss this further and can provide additional actuarial data, clinical evidence summaries, or resources from the Obesity Medicine Association or the Business Group on Health upon request.

We respectfully ask that GLP-1 anti-obesity medication coverage be included in the [PLAN YEAR] benefits review discussion.

Thank you for considering this request.

Respectfully submitted,

[EMPLOYEE NAME 1], [DEPARTMENT]
[EMPLOYEE NAME 2], [DEPARTMENT]
[EMPLOYEE NAME 3], [DEPARTMENT]
[ADD ADDITIONAL SIGNATORIES]

Tip: More signatories = significantly more impact. Aim for at least 5 before submitting.

What to Do If HR Says No

A first "no" rarely means "never." It usually means one of a few things:

If they say "it's too expensive"

Ask them to share the actuarial modeling behind that conclusion. Point to employers of similar size who have added coverage cost-effectively using PA guardrails. Offer to connect them with the Business Group on Health (businessgrouphealth.org), which publishes data on employer GLP-1 coverage costs and outcomes.

If they say "we're fully insured, not self-funded"

Fully insured plans can still advocate to their insurance carrier for formulary additions — particularly at renewal. Ask HR to raise this with the carrier at the next renewal negotiation. You can also provide the same business case data for the carrier's consideration.

If they say "maybe next year"

Get the specific timeline. Ask to be notified when the next formulary review begins. Submit your request again formally at that time, with updated signatories and any new clinical evidence published in the interim.

If there's no response

Escalate respectfully to the Chief People Officer or Chief Financial Officer. Frame it as both a health equity issue and a financial risk management issue. Request a 15-minute meeting to present the data in person.

Resources for HR and Benefits Teams

Business Group on Health: businessgrouphealth.org — publishes annual employer health benefits surveys including GLP-1 adoption data
Obesity Medicine Association: obesitymedicine.org — clinical resources and employer engagement materials
Obesity Action Coalition: obesityaction.org — patient advocacy resources including employer outreach guides
STOP Obesity Alliance: stopobesityalliance.org — policy and employer engagement materials
NEJM SELECT trial (2023): The landmark semaglutide cardiovascular outcomes study, free to access at NEJM.org

Related Resources

Letter Templates

All GLP-1 Letter Templates — Prior Auth, Appeal, HR & More

Cost of Inaction

The True Financial Cost of Not Treating Obesity

Insurance Guide

Step-by-Step Guide to GLP-1 Insurance Coverage

Cost Guide

Why GLP-1 Programs Cost So Much — and How to Pay Less